ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons"

  • Abstract Number: 168 • 2020 Pediatric Rheumatology Symposium

    Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity

    Keila Veiga1, Noa Schwartz 2, William Shipman 1, Marvin Sandoval 3, Thomas Li 1, Yurii Chinenov 1, David Oliver 1, Ali Jabbari 4, James Krueger 5, Sarah Taber 1, Niroshana Anandasabapathy 6 and Theresa Lu 1, 1Hospital for Special Surgery, New York, 2Albert Einstein College of Medicine/Montefiore Medical Center, New York, 3Weill Cornell Graduate School of Medical Sciences, New York, 4University of Iowa, Iowa City, 5Rockefeller Center, New York, 6Weill Cornell Medicine, New York

    Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus.  Lesions can be disfiguring and have a negative impact on quality of…
  • Abstract Number: 005 • 2020 Pediatric Rheumatology Symposium

    Single Cell Sequencing of the Skin to Define Cell Populations of Interest in Localized Scleroderma (LS)

    Emily Mirizio 1, Wei Chen 2, Tao Sun 2, Tracy Tabib 3, Kaila Schollaert-Fitch 1, Robert Lafyatis 4, Heidi Jacobe 5 and Kathryn Torok1, 1Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, 2Research Computing Core at Children's Hospital of Pittsburgh, Pittsburgh, 3Univ of Pittsburgh Med Ctr, Pittsburgh, 4Univ of Pittsburgh Med Ctr, Pittsburgh, Pittsburgh, 5University of Texas Southwestern Medical Ctr, Dallas

    Background/Purpose: Scleroderma is an autoimmune disorder involving inflammatory driven fibrosis, which encompasses systemic sclerosis (SSc) and localized scleroderma (LS).  LS and SSc share histological characteristics,…
  • Abstract Number: 027 • 2020 Pediatric Rheumatology Symposium

    Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition

    Sofia Torreggiani1, Pascal Pillet 2, Fabiano de Oliveira Poswar 3, Anna Kozlova 4, Anna Shcherbina 4, Marietta De Guzman 5, Jacob Mitchell 6, Gina A. Montealegre Sanchez 7, Katherine Townsend 8, Kim Johnson 9, Adriana Almeida de Jesus 10 and Raphaela Goldbach-Mansky 11, 1National Institutes of Health, Bethesda, 2Bordeaux Cedex, France, 3Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 4Center for Pediatric Hematology, Oncology, Immunology, Moscow, Russia, 5Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 6NIAID, NIH, Bethesda, 7NIH/ NIAID, Rockville, 8NIH, 9NIH, NIAID, Bethesda, 10NIAID, NIH, Silver Spring, 11NIH/NIAID, Potomac

    Background/Purpose: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy And Elevated Temperature (CANDLE) Syndrome is an autoinflammatory interferonopathy caused by mutations in the genes encoding for components…
  • Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis 1, Denise Pires Marafon 2, Ivan Caiello 2, Manuela Pardeo 2, Giulia Marucci 2, Emanuela Sacco 2, Giusi Prencipe 2, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
  • Abstract Number: 080 • 2020 Pediatric Rheumatology Symposium

    Therapeutic Interferon Gamma Neutralization with Emapalumab in Patients with NRLC4- and CDC42-Associated Diseases Characterized by Recurrent and Severe Hemophagocytic Lymphohistiocytosis

    Claudia Bracaglia1, Antonella Insalaco 1, Giulia Marucci 1, Manuela Pardeo 1, Emanuela Sacco 1, Virginia Messia 1, Giusi Prencipe 1, Ivan Caiello 1, Sarka Fingerhutova 2, Pavla Dolezalova 2, Veronica Asnaghi 3, Maria Ballabio 3, Cristina de Min 3 and Fabrizio De Benedetti 1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, 3Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: Interferon gamma (IFNγ) is a pivotal mediator of HLH. Emapalumab (a fully human anti-IFNγ monoclonal antibody) is efficacious in patients with primary HLH. In…
  • Abstract Number: 140 • 2020 Pediatric Rheumatology Symposium

    Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade

    Claas Hinze1, Tanja Hinze 2, Helmut Wittkowski 1, Christoph Kessel 1, Sabrina Fuehner 1 and Dirk Foell 1, 1University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 2Muenster, Nordrhein-Westfalen, Germany

    Background/Purpose: Most, but not all, patients with systemic juvenile idiopathic arthritis (systemic JIA) respond to therapy with interleukin (IL)-1 blocking agents but predictive factors have…
  • Abstract Number: L06 • 2019 ACR/ARP Annual Meeting

    Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids

    Fabrizio De Benedetti1, Paul Brogan 2, Alexei A. Grom 3, Pierre Quartier 4, Rayfel Schneider 5, Jordi Antón 6, Claudia Bracaglia 7, Manuela Pardeo 8, Giulia Marucci 8, Emanuela Sacco 9, Despina Eleftheriou 10, Charalampia Papadopoulou 11, Philippe Jacqmin 12, maria ballabio 13 and Cristina de Min 13, 1Bambino Gesù Children's Hospital, Rome, Italy, 2Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Necker Hospital, Paris, France, 5Hospital for Sick Children, Toronto, ON, Canada, 6Hospital Sant Joan de Déu, Barcelona, Spain, 7Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 8Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 9Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, 10UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section,, london, United Kingdom, 11UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section, london, United Kingdom, 12MnS, Dinant, Belgium, 13Sobi AG, basel, Switzerland

    Background/Purpose: MAS is a severe complication of rheumatic diseases, most frequently sJIA and adult-onset Still’s disease. It is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias,…
  • Abstract Number: 2026 • 2019 ACR/ARP Annual Meeting

    MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27

    Daiga Kishimoto1, Ryusuke Yoshimi 1, Yosuke Kunishita 1, Yumiko Sugiyama 2, Takaaki Komiya 1, Natsuki Sakurai 3, Reikou Kamiyama 1, Yohei Kirino 4 and Hideaki Nakajima 4, 1Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatic Diseases / Yokohama City University Medical Center, Yokohama, Japan, 3Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama City, Japan, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Type Ⅰ interferons (IFN) contribute to antiviral innate immune responses. Upon viral infection, pattern recognition receptors trigger TANK-binding kinase 1 (TBK1) activation and lead…
  • Abstract Number: 2032 • 2019 ACR/ARP Annual Meeting

    Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation

    Goh Murayama1, Asako Chiba 2, Ayako Makiyama 3, Taiga Kuga 4, Ken Yamaji 4, Naoto Tamura 4 and Sachiko Miyake 2, 1Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, 3Juntendo University School of Medicine, Tokyo, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Interferona (IFNa) is increased and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes…
  • Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting

    IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells

    Angie Hammond1, Sean Parghi 1, Nathan Wright 1, Ethan Grant 1, James Taylor 1 and Matthew Warr 1, 1Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…
  • Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting

    PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease

    Ian Bruce1, Alireza Nami 2, Erik Schwetje 3, M Edward Pierson 4, Yen Lin Chia 5, Denison Kuruvilla 5, Gabriel Abreu 6, Raj Tummala 3 and Catharina Lindholm 6, 1University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 2Joint & Muscle Medical Care, Charlotte, NC, US, Charlotte, NC, 3AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, 4AstraZeneca, Gaithersburg, MD, US, Gaithersburg, MD, 5AstraZeneca, South San Francisco, CA, US, South San Francisco, CA, 6AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…
  • Abstract Number: 2739 • 2019 ACR/ARP Annual Meeting

    Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis

    Mika Tabata1, Kavita Sarin 2, Karen Page 3, Christine Huard 3, Shanrong Zhao 3, Donald Bennett 3, Jillian Johnson 3, Kristen Johnson 3 and David Fiorentino 2, 1Stanford University School of Medicine, Stanford, CA, 2Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, 3Pfizer, Boston

    Background/Purpose: Interferon (IFN) signaling is upregulated in dermatomyositis (DM) and thought to play a role in pathogenesis. An IFN gene signature in peripheral blood of…
  • Abstract Number: 78 • 2019 ACR/ARP Annual Meeting

    Ultraviolet Light Induces Increased T Cell Activation in Lupus-Prone Mice via Type I Interferon-Dependent Inhibition of T Regulatory Cells

    Sonya Wolf-Fortune 1, Shannon Estadt 1, Jonathan Theros 1, Tyson Moore 1, Jason Ellis 1, Jianhua Liu 1, Tamra Reed 1, Chaim Jacob 1, Johann Gudjonsson 1 and J Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI

    Background/Purpose: Ultraviolet (UV) light is a known trigger of skin and possibly systemic inflammation in systemic lupus erythematosus (SLE) patients. Although type I interferons (IFN)…
  • Abstract Number: 2808 • 2019 ACR/ARP Annual Meeting

    Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block

    Miao Chang1, Robert Clancy 1 and Jill Buyon 1, 1NYU School of Medicine, New York

    Background/Purpose: Since one of the strongest associations with antibodies (abs) to SSA/Ro (Ro60) is the development of congenital heart block (CHB), this model provides an…
  • Abstract Number: 88 • 2019 ACR/ARP Annual Meeting

    Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets

    Irene Cecchi1, Massimo Radin 1, Elena Rubini 1, Silvia Grazietta Foddai 1, Ana Suarez 2, Elisa Menegatti 1, Dario Roccatello 1, Savino Sciascia 3 and Javier Rodriguez Carrio 2, 1University of Turin, Turin, Italy, 2University of Oviedo, Oviedo, Spain, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy

    Background/Purpose: Type I Interferons (IFN) play a key role in the pathogenesis and evolution of various autoimmune diseases. Previous studies have demonstrated that the expression…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology